<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01041807</url>
  </required_header>
  <id_info>
    <org_study_id>0954-349</org_study_id>
    <secondary_id>2009_004</secondary_id>
    <nct_id>NCT01041807</nct_id>
  </id_info>
  <brief_title>Cozaar XQ Re-examination Study (MK-0954-349)</brief_title>
  <official_title>Re-examination Study for General Drug Use to Assess the Safety and Efficacy Profile of COZAAR XQ in Usual Practice</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This survey is conducted for preparing application material for re-examination under the
      Pharmaceutical Affairs Law and its Enforcement Regulation; its aim is to reconfirm the
      clinical usefulness of COZAAR XQ through collecting the safety and efficacy information
      according to the Re-examination Regulation for New Drugs.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with any adverse experience</measure>
    <time_frame>Up to 14 days after last treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of sitting systolic and diastolic blood pressure (SiSBP, SiDBP) after treatment and overall efficacy evaluation by investigator</measure>
    <time_frame>At 8 weeks after first treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of sitting systolic and diastolic blood pressure (SiSBP, SiDBP) after treatment and overall efficacy evaluation by investigator</measure>
    <time_frame>At 24 weeks after first treatment</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">669</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>All participants</arm_group_label>
    <description>Participants with hypertension treated with amlodipine/losartan(Cozaar XQ)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>amlodipine/losartan</intervention_name>
    <description>amlodipine/losartan (COZAAR XQ) prescribed according to the current local label</description>
    <arm_group_label>All participants</arm_group_label>
    <other_name>COZAAR XQ</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Participants with essential hypertension not adequately controlled with amlodipine or
        losartan monotherapy; initial therapy for participants with stage 2 hypertension
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Participant with essential hypertension

          -  Participant who is treated with COZAAR XQ within local label for the first time

        Exclusion criteria:

          -  Participant who is treated with COZAAR XQ before contract and out of enrollment period

          -  Participant who has a contraindication to COZAAR XQ according to the local label
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Korea, Republic of</country>
  </removed_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 31, 2009</study_first_submitted>
  <study_first_submitted_qc>December 31, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 1, 2010</study_first_posted>
  <last_update_submitted>April 9, 2015</last_update_submitted>
  <last_update_submitted_qc>April 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Losartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

